The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Refining intermediate-risk (IR) stratification in patients (Pts) with metastatic renal cell carcinoma (mRCC) receiving first-line (1L) immunotherapy (IO) within one year of diagnosis (Dx): Findings from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
 
Razane El Hajj Chehade
No Relationships to Disclose
 
Rashad Nawfal
No Relationships to Disclose
 
Karl Semaan
No Relationships to Disclose
 
Marc Eid
No Relationships to Disclose
 
Eddy Saad
Research Funding - EMD Serono; Genentech/Roche (Inst); Oncohost
 
Marc Machaalani
No Relationships to Disclose
 
Emre Yekeduz
No Relationships to Disclose
 
Clara Steiner
No Relationships to Disclose
 
Wassim Daoud Khatoun
No Relationships to Disclose
 
David Maj
No Relationships to Disclose
 
Martin Zarba
No Relationships to Disclose
 
Connor Wells
No Relationships to Disclose
 
Sumanta Pal
Speakers' Bureau - IntrinsiQ; MJH Life Sciences; Peerview
Travel, Accommodations, Expenses - crispr therapeutics; Exelixis; Ipsen
 
Cristina Suárez
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Eisai; EUSA Pharma; Ipsen; Merck Sharp & Dohme; Pfizer; Roche/Genentech (Inst)
Speakers' Bureau - Bristol-Myers Squibb; Eisai; Ipsen; Merck Sharp & Dohme; Pfizer; Roche/Genentech
Research Funding - AB Science (Inst); Aragon Pharmaceuticals (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi Aventis GmbH (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Ipsen; Roche
 
Kosuke Takemura
Honoraria - Bristol-Myers Squibb; MSD; Ono Pharmaceutical; Takeda
Research Funding - Suzuki Foundation for Urological Medicine; Takeda
Travel, Accommodations, Expenses - ESMO
 
Haoran Li
No Relationships to Disclose
 
Sylvan Baca
Employment - Dana Farber Cancer Hospital
Consulting or Advisory Role - Precede Bio
Patents, Royalties, Other Intellectual Property - Precede Bio
 
Wanling Xie
Consulting or Advisory Role - Convergent Therapeutics; Prostate Cancer Clinical Trial Consortium
 
Daniel Heng
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Eisai; Ipsen; Janssen; Merck; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Exelixis (Inst); Ipsen (Inst); Novartis (Inst); Pfizer (Inst)
 
Toni Choueiri
No Relationships to Disclose